Rapid Respiratory Microbiological Point-of-Care Testing and Antibiotic Use in Primary Care
JAMA Internal Medicine · 01.07.2026 · 186 (7) · 817
DOI: 10.1001/jamainternmed.2026.1426 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.07.2026. Verfasst von Alastair D Hay und 20 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Academic Primary Care, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, United Kingdom. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Respiratory Tract Infections, Point-of-Care Testing. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
IMPORTANCE Most antibiotic prescribing takes place in primary care, driving antimicrobial resistance, a top-10 threat to global public health. There is considerable international interest in whether rapid multiplex microbiological point-of-care testing (RM-POCT) can safely reduce antibiotic prescribing in primary care. OBJECTIVE To investigate whether the use of a RM-POCT can safely reduce same-day antibiotic prescribing for children and adults presenting to primary care with respiratory infections. DESIGN, SETTING, AND PARTICIPANTS This parallel-group randomized clinical trial was conducted at 16 general practices in Southwest England between December 2022 and April 2024. Patients were eligible if they were aged 12 months or older, presented with any clinician-diagnosed acute (≤21 days) respiratory tract infection, and the patient or clinician believed antibiotic treatment was, or might be, necessary. Participants were randomized (1:1) to RM-POCT or usual care. The research team, including those conducting statistical analyses, were unaware of group allocation. Data were analyzed from November 21, 2024, to March 13, 2025. INTERVENTION Patients in the intervention group were tested with RM-POCT to indicate the presence or absence of 19 respiratory viral pathogens and 4 atypical bacteria in approximately 45 minutes. MAIN OUTCOMES AND MEASURES The primary outcome was same-day antibiotic prescribing. The safety outcome was patient-reported symptom severity on days 2 to 4. RESULTS Among 552 included patients (mean [SD] age, 40.0 [21.2] years; 349 [63%] female), 276 were randomized to the intervention group and 276 to usual care. Primary outcome data were available for all participants, and safety outcome data were available in 216 intervention participants (78%) and 203 usual care participants (74%). Same-day antibiotics were prescribed to 124 participants (45%) in each group (odds ratio [OR], 1.00 [95% CI, 0.71 to 1.41]; P > .99). Prespecified subgroup analyses showed evidence of differentially reduced antibiotic prescribing in participants from whom a virus was detected (OR, 0.35 [95% CI, 0.20 to 0.63]; P for interaction < .001) and those with chronic lung disease (OR, 0.55 [95% CI, 0.28 to 1.09]; P for interaction = .046) but not children younger than 16 years (OR, 1.75 [95% CI, 0.64 to 4.74]; P for interaction = .24), nor where patients and clinicians disagreed on antibiotic necessity (OR, 1.12 [95% CI, 0.63 to 1.98]; P for interaction = .53). There was no difference in symptom severity on days 2 to 4 between groups (difference in means, 0.09 [95% CI, −0.10 to 0.27]; P = .36). CONCLUSIONS AND RELEVANCE In this randomized clinical trial among patients with respiratory tract infections being considered for antibiotic treatment in primary care, use of an RM-POCT did not reduce same-day antibiotic prescribing or worsen patient outcomes. Trial Registration isrctn.org Identifier: ISRCTN16039192 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Academic Primary Care, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, United Kingdom.
- Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
- Centre for Applied Excellence in Skin and Allergy Research, University of Bristol, Bristol, United Kingdom.
- Whiteladies Medical Group, Bristol, United Kingdom.
- UK Health Security Agency South West Regional Laboratory, Southmead Hospital, Bristol, United Kingdom.
- Bristol, United Kingdom.
Zitieren
APA
Hay, A. D., Abbs, S., Ridd, M., Granier, S., Lane, J. A., Muir, P., Taylor, J., Young, G., Eastwood, K., Dash, H., Bradshaw, L., Clarke, R., Lui, M., Bridgeman, E., Brierley, R. C. M., Brown, E., Thornton, H. V., Mitchell, P. M., Zhu, L., …, & Metcalfe, C. (2026). Rapid Respiratory Microbiological Point-of-Care Testing and Antibiotic Use in Primary Care. JAMA Internal Medicine, 186(7), 817. https://doi.org/10.1001/jamainternmed.2026.1426
Vancouver
Hay AD, Abbs S, Ridd M, Granier S, Lane JA, Muir P, et al. Rapid Respiratory Microbiological Point-of-Care Testing and Antibiotic Use in Primary Care. JAMA Internal Medicine. 2026;186(7):817. doi:10.1001/jamainternmed.2026.1426
BibTeX
@article{Hay2026,
author = {Hay, Alastair D and Abbs, Samantha and Ridd, Matthew and Granier, Stephen and Lane, J Athene and Muir, Peter and Taylor, Jodi and Young, Grace and Eastwood, Kathy and Dash, Hayley and Bradshaw, Lynne and Clarke, Rebecca and Lui, Mandy and Bridgeman, Emma and Brierley, Rachel C M and Brown, Emily and Thornton, Hannah V and Mitchell, Paul M and Zhu, Liang and Yardley, Lucy and Metcalfe, Chris},
title = {Rapid Respiratory Microbiological Point-of-Care Testing and Antibiotic Use in Primary Care},
journal = {JAMA Internal Medicine},
year = {2026},
volume = {186},
number = {7},
pages = {817},
doi = {10.1001/jamainternmed.2026.1426}
}
EUVIMED